University of Texas's MD Anderson Cancer Center: Majority of Patients Responded in CAR T-Cell Trial for Mantle Cell Lymphoma
April 03, 2020
April 03, 2020
HOUSTON, Texas, April 3 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy. Findings were published in the April 1online issue of the New England Journal of Medic . . .
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy. Findings were published in the April 1online issue of the New England Journal of Medic . . .